Guggenheim reiterates Biogen stock rating on Alzheimer’s drug data

Guggenheim reiterated a Buy rating on Biogen with a $260 price target, implying roughly 36% upside from the current $191.37 share price. The CELIA Phase 2 study of diranersen showed slowing of clinical decline and sustained reductions in CSF tau and tau PET biomarkers, though it missed its primary dose-response endpoint. Management plans to advance the anti-tau program into Phase 3, and full data will be presented at AAIC in July.

Analysis

The market is rewarding the optionality embedded in a plausible Alzheimer’s signal, but the bigger implication is that BIIB is starting to look less like a one-drug neuro story and more like a platform call on whether anti-tau can become the next durable CNS franchise. The key second-order effect is not the headline pipeline value itself; it is the re-rating of BIIB’s probability-weighted innovation engine after a long period where investors discounted the company as a mature cash-flow asset with limited growth vectors.

The primary-endpoint miss actually leaves a cleaner setup for Phase 3 than a conventional win would have: management can now design around the observed dose/response inversion and choose a regimen optimized for biology, not statistics. That matters because the lowest-dose signal reduces the risk that efficacy is merely exposure-driven noise, while the biomarker package gives regulators a plausible mechanistic bridge. If Phase 3 can preserve even part of that separation over 12–18 months, the market will likely capitalize a multi-billion-dollar Alzheimer’s opportunity rather than debate statistical elegance.

Consensus may be underestimating how asymmetric the read-through is for the whole CNS basket. A credible tau success would pressure competitors pursuing amyloid-only positioning and could redirect partnering capital toward biomarker-led neuro programs, while a later-stage failure would likely compress the stock back toward a lower-growth biotech multiple quickly. The near-term risk is a classic “good enough to move the stock, not good enough to de-risk the science” dynamic into AAIC: expect volatility to stay elevated until full data clarify effect size, durability, and whether the lowest-dose result holds up outside a small Phase 2 dataset.

Key Decisions for Investors

• Long BIIB into the AAIC data release; best risk/reward is a staged entry on any post-rally consolidation, with a 3-6 month horizon and a target range near prior analyst fair value if Phase 3 design looks credible.
• Buy BIIB call spreads 1-2 months out to capture data-event convexity while limiting premium bleed; structure around the July conference window where implied volatility is likely still favorable versus realized move potential.
• Pair trade: long BIIB / short a basket of lower-quality CNS names without near-term clinical catalysts, to isolate the tau-platform re-rating from broader biotech beta.
• If BIIB spikes materially ahead of full data, trim into strength rather than chase; the biggest failure mode is a “buy the rumor, sell the nuanced data” reaction if the primary endpoint miss dominates the narrative.